Prosthetic Joint Infection Clinical Trial
Official title:
Rapid Diagnosis of Prosthetic Joint Infection by Matrix-assisted Laser Desorption Ionization Time-of-flight Mass Spectrometry
This is a prospective cohort study. All patients presenting for periprosthetic joint
infection and requiring debridement only or resection arthroplasty will be eligible. The
synovial joint fluid will be sampled before the arthrotomy at the operation room.
The purpose of this study will be to evaluate that 1) the concordance of organism
identification by the direct identification of MALTI-TOF MS versus routine identification of
MALTI-TOF MS and conventional cultures and 2) the timing of preliminary strain identification
by the direct identification of MALTI-TOF MS, routine identification of MALTI-TOF MS and
conventional cultures in patients with periprosthetic joint infection.
Material and Methods
1. Patients who have a high probability of infection based on the Musculoskeletal Infection
Society (MSIS) criteria and are scheduled for debridement only or debridement with
implant removal, will be invited to enroll the study after signed informed consent.
The synovial joint fluid will be sampled before the arthrotomy at the operation room.
Aspirates will be collected under an aseptic technique with an 18-Fr sterile syringe
with a minimum amount of 14 ccs. The sample will be divided between MALDI-TOF mass
spectrometry in standard blood culture bottles (10 ccs), wound culture tube (2 ccs), and
synovial fluid analysis (2 ccs). The samples will be delivered to microbiology
laboratory within a 2-hour period.
2. Bacterial culture and conventional identification Bacterial identification will be
performed by the conventional method using the Vitek 2 system. For the conventional
culture, 1 µL of well-mixed synovial joint fluid will be inoculated and spread onto
blood agar plates and MacConkey agar plates using a sterile plastic disposable loop.
Plates will be incubated in an aerobic atmosphere at 37℃ for 18-24 hr. When bacterial
growth is observed, the colonies on blood agar will be counted, and colonies from both
types of plates will be identified by using the Vitek 2 system.
3. MALDI-TOF MS identification The suspension obtained following the above sample
preparation will be centrifuged at 13,000g for 2 minutes, and the supernatant will be
discarded. The pellet will be centrifuged at 13,000g for another 2 minutes prior to the
removal of the residual ethanol. Fifty microliters of formic acid (70% v/v) and 50 mL of
100% acetonitrile will be added to the pellet, and mixed thoroughly after each reagent
is added. The suspension will be centrifuged again at 13,000g for another 2 minutes, and
1 mL of the supernatant will be spotted onto the steel target plate. Analysis will be
performed following air-drying of 1 mL a-cyano-4-hydroxycinnamic acid matrix solution
placed onto the dried sample spot in duplicate.
Mass spectra profiles will be acquired using a microflex LT MALDI-TOF mass spectrometer
(Bruker Daltonics, Bremen, Germany) following the manufacturer's settings. Spectra will
be recorded in the linear positive mode at a laser frequency of 60 Hz within a mass
range from 2000 Da to 20,000 Da. All bacteria identifications will be performed by
MALDI-TOF Biotyper RTC and the Bruker MALDI Biotyper 3.1 software and library (4613
isolates; Bruker Daltonics). Criteria used for microorganism analysis and identification
will be as recommended by the manufacturer.
4. Statistical analysis Time to identification will be determined as the time from colony
formation to the time at which the final result is reported to a physician. Statistical
analysis will be performed to compare the three methods using Chi-square tests. The
level of statistical significance will be set at p < 0.05.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04067843 -
Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
|
N/A | |
Enrolling by invitation |
NCT05247281 -
NGS vs Culture Outcomes for Treatment of PJI
|
N/A | |
Withdrawn |
NCT05269121 -
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
Recruiting |
NCT02801253 -
Cohort of Prosthetic Joint Infections
|
||
Completed |
NCT03694925 -
Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
|
||
Completed |
NCT03721328 -
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
|
Phase 2 | |
Withdrawn |
NCT04787250 -
Bacteriophage Therapy in Patients With Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
Recruiting |
NCT03307109 -
Quality of Life in Patients Having a Prosthetic Joint Infection
|
||
Recruiting |
NCT04661345 -
Identification of Molecular Marker of Coagulase-negative Staphylococci for the Diagnosis of Prosthetic Joint Infections
|
||
Recruiting |
NCT02805803 -
Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection.
|
N/A | |
Completed |
NCT02413034 -
The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures
|
N/A | |
Recruiting |
NCT03784807 -
New Strategies for Biofilm Related Infections
|
||
Completed |
NCT04662632 -
Abbreviated Protocol for Two-Stage Exchange
|
Phase 2 | |
Not yet recruiting |
NCT04390607 -
Leukocyte Esterase Sensor Test
|
||
Recruiting |
NCT04650607 -
Phage Safety Cohort Study
|
||
Active, not recruiting |
NCT04946500 -
Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)
|
||
Recruiting |
NCT04762706 -
Measuring Distress in Prosthetic Joint Infection Using a Standardized Metric: CRUTCH Pathway Pilot.
|
N/A | |
Withdrawn |
NCT05269134 -
Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)
|
Phase 2 | |
Not yet recruiting |
NCT05239312 -
Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital
|
||
Completed |
NCT04294862 -
Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty
|
Phase 1 |